Radioimmunotherapy (RIT) allows for the delivery of high doses of therapeutic radiation to tumor cells while minimizing exposure to normal cells. RIT works by using engineered proteins called antibodies to home in on tumors in the body while carrying radioactive payloads to destroy the tumor cells. This form of therapeutic liquid radiation harnesses the power of immunotherapy to specifically target cancer cells with the potency of nuclear energy designed to create one of the most effective ways to obliterate all traces of tumor cells.
Y-mAbs takes a unique approach to RIT which is designed to allow for higher potency and greater safety to deliver therapeutic radiation to tumors using compartmental radioimmunotherapy.
Y-mAbs has partnered with Memorial Sloan-Kettering Cancer Center and Massachusetts Institute of Technology in a worldwide exclusive license and research collaboration agreement to develop and commercialize antibody constructs based on the novel Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy (“PRIT”) technology platform.
The SADA PRIT technology platform utilizes a targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target. Unbound constructs predictably disassemble into smaller antibody fragments and are excreted through the kidneys within hours after administration. In a second infusion, a radioactive payload binds to the antibody constructs to radiate the tumor.
